Intervention Review

You have free access to this content

Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease

  1. Caroline A Crowther1,2,*,
  2. Zarko Alfirevic3,
  3. Shanshan Han2,
  4. Ross R Haslam4

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 21 NOV 2013

Assessed as up-to-date: 17 JUL 2013

DOI: 10.1002/14651858.CD000019.pub3


How to Cite

Crowther CA, Alfirevic Z, Han S, Haslam RR. Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD000019. DOI: 10.1002/14651858.CD000019.pub3.

Author Information

  1. 1

    The University of Auckland, Liggins Institute, Auckland, New Zealand

  2. 2

    The University of Adelaide, ARCH: Australian Research Centre for Health of Women and Babies, The Robinson Institute, Discipline of Obstetrics and Gynaecology, Adelaide, South Australia, Australia

  3. 3

    The University of Liverpool, Department of Women's and Children's Health, Liverpool, UK

  4. 4

    The University of Adelaide, Department of Perinatal Medicine, Adelaide, South Australia, Australia

*Caroline A Crowther, Liggins Institute, The University of Auckland, Private Bag 92019, 85 Park Road, Auckland, New Zealand. caroline.crowther@adelaide.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 21 NOV 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 1 Death prior to hospital discharge.
[Analysis 1.2]
Analysis 1.2. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 2 Chronic lung disease.
[Analysis 1.3]
Analysis 1.3. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 3 Respiratory distress syndrome.
[Analysis 1.4]
Analysis 1.4. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 4 Chronic lung disease or death.
[Analysis 1.5]
Analysis 1.5. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 5 Need for oxygen therapy.
[Analysis 1.6]
Analysis 1.6. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 6 Severe respiratory distress syndrome.
[Analysis 1.7]
Analysis 1.7. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 7 Use of respiratory support.
[Analysis 1.8]
Analysis 1.8. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 8 Admission to neonatal intensive care unit.
[Analysis 1.9]
Analysis 1.9. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 9 Intraventricular haemorrhage.
[Analysis 1.10]
Analysis 1.10. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 10 Severe intraventricular haemorrhage.
[Analysis 1.11]
Analysis 1.11. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 11 Air leak syndrome.
[Analysis 1.12]
Analysis 1.12. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 12 Pulmonary haemorrhage.
[Analysis 1.13]
Analysis 1.13. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 13 Necrotising enterocolitis.
[Analysis 1.14]
Analysis 1.14. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 14 Patent ductus arteriosus.
[Analysis 1.15]
Analysis 1.15. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 15 Low Apgar score at 5 minutes.
[Analysis 1.16]
Analysis 1.16. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 16 Use of surfactant.
[Analysis 1.17]
Analysis 1.17. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 17 Gestational age at birth.
[Analysis 1.18]
Analysis 1.18. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 18 Motor delay at follow-up.
[Analysis 1.19]
Analysis 1.19. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 19 Motor impairment at follow-up.
[Analysis 1.20]
Analysis 1.20. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 20 Fine motor delay at follow-up.
[Analysis 1.21]
Analysis 1.21. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 21 Sensory impairment at follow-up.
[Analysis 1.22]
Analysis 1.22. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 22 Language delay at follow-up.
[Analysis 1.23]
Analysis 1.23. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 23 Social delay at follow-up.
[Analysis 1.24]
Analysis 1.24. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 24 Any neurodevelopmental abnormality at follow-up.
[Analysis 1.25]
Analysis 1.25. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 25 Bayley Mental Developmental Index.
[Analysis 1.26]
Analysis 1.26. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 26 Bayley Psychomotor Developmental Index.
[Analysis 1.27]
Analysis 1.27. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 27 Bayley Behavioural Rating Scales (18 months).
[Analysis 1.28]
Analysis 1.28. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 28 Bayley Language Developmental Age (18 months).
[Analysis 1.29]
Analysis 1.29. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 29 Bayley Cognitive Developmental Age (18 months).
[Analysis 1.30]
Analysis 1.30. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 30 Serious neurological abnormality at follow-up.
[Analysis 1.31]
Analysis 1.31. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 31 Opthalmological or hearing abnormalities at follow-up.
[Analysis 1.32]
Analysis 1.32. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 32 Maternal nausea.
[Analysis 1.33]
Analysis 1.33. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 33 Maternal vomiting.
[Analysis 1.34]
Analysis 1.34. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 34 Maternal light headedness.
[Analysis 1.35]
Analysis 1.35. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 35 Urgency of micturition.
[Analysis 1.36]
Analysis 1.36. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 36 Maternal facial flushing.
[Analysis 1.37]
Analysis 1.37. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 37 Maternal systolic blood pressure rise >= 25 mmHg.
[Analysis 1.38]
Analysis 1.38. Comparison 1 TRH + steroids versus steroids alone (intention-to-treat), Outcome 38 Maternal diastolic blood pressure rise >= 15 mmHg.
[Analysis 2.1]
Analysis 2.1. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 1 Death prior to hospital discharge.
[Analysis 2.2]
Analysis 2.2. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 2 Chronic lung disease.
[Analysis 2.3]
Analysis 2.3. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 3 Respiratory distress syndrome.
[Analysis 2.4]
Analysis 2.4. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 4 Chronic lung disease or death.
[Analysis 2.5]
Analysis 2.5. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 5 Need for oxygen therapy.
[Analysis 2.6]
Analysis 2.6. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 6 Severe respiratory distress syndrome.
[Analysis 2.7]
Analysis 2.7. Comparison 2 TRH + steroids versus steroids alone (dose of TRH subgroups), Outcome 7 Use of respiratory support.
[Analysis 3.1]
Analysis 3.1. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 1 Death prior to hospital discharge.
[Analysis 3.2]
Analysis 3.2. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 2 Chronic lung disease.
[Analysis 3.3]
Analysis 3.3. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 3 Respiratory distress syndrome.
[Analysis 3.4]
Analysis 3.4. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 4 Chronic lung disease or death.
[Analysis 3.5]
Analysis 3.5. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 5 Need for oxygen therapy.
[Analysis 3.6]
Analysis 3.6. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 6 Severe respiratory distress syndrome.
[Analysis 3.7]
Analysis 3.7. Comparison 3 TRH + steroids versus steroids alone (timing of delivery subgroups), Outcome 7 Use of respiratory support.
[Analysis 4.1]
Analysis 4.1. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 1 Death prior to hospital discharge.
[Analysis 4.2]
Analysis 4.2. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 2 Chronic lung disease.
[Analysis 4.3]
Analysis 4.3. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 3 Respiratory distress syndrome.
[Analysis 4.4]
Analysis 4.4. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 4 Chronic lung disease or death.
[Analysis 4.5]
Analysis 4.5. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 5 Need for oxygen therapy.
[Analysis 4.6]
Analysis 4.6. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 6 Severe respiratory distress syndrome.
[Analysis 4.7]
Analysis 4.7. Comparison 4 TRH + steroids versus steroids alone (optimally treated variously defined), Outcome 7 Use of respiratory support.
[Analysis 5.1]
Analysis 5.1. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 1 Death prior to hospital discharge.
[Analysis 5.2]
Analysis 5.2. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 2 Chronic lung disease.
[Analysis 5.3]
Analysis 5.3. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 3 Respiratory distress syndrome.
[Analysis 5.4]
Analysis 5.4. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 4 Chronic lung disease or death.
[Analysis 5.5]
Analysis 5.5. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 5 Need for oxygen therapy.
[Analysis 5.6]
Analysis 5.6. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 6 Severe respiratory distress syndrome.
[Analysis 5.7]
Analysis 5.7. Comparison 5 TRH + steroids versus steroids alone (high-quality trials), Outcome 7 Use of respiratory support.